Relay Therapeutics Shares Reclaim Offer Price as Traders Eye June
Relay Therapeutics shares traded at $14.50 Thursday, holding above last week’s $12 public offering price after raising $296.8 million from a stock sale. The company reported early Phase 2 data showing 60% of evaluable patients with PIK3CA-driven vascular anomalies responded to its drug zovegalisib. Management will present at two major healthcare conferences in June. Relay ended Q1 with $642.1 million in cash.